**Supporting Statement A**

**OMB control # 0920-0775**

*Formative Research to Develop Social Marketing Campaigns- Routine HIV Testing for Emergency Medicine Physicians, Prevention Is Care, and Partner Services*

*March 1, 2011*

**Project officer:**

**Donata R. Green, Ph.D.**   
Centers for Disease Control and Prevention   
Division of HIV/AIDS Prevention   
8 Corporate Blvd.   
Mail Stop E-49, Room 5020   
Atlanta, GA 30329   
(404) 639-3869 office   
(404) 639-2007 fax

dqg7@cdc.gov

**TABLE OF Contents**

**Section**

[A. Justification.](#_Toc176078234)

[1. Circumstances Making the Collection of Information Necessary](#_Toc176078235)

[2. Purpose and Use of the Information Collection](#_Toc176078236)

[3. Use of Improved Information Technology and Burden Reduction](#_Toc176078237)

[4. Efforts to Identify Duplication and Use of Similar Information](#_Toc176078238)

[5. Impact on Small Businesses or Other Small Entities](#_Toc176078239)

[6. Consequences of Collecting the Information Less Frequently](#_Toc176078240)

[7. Special Circumstances Relating to the Guidelines of 5 CFR 1320.5](#_Toc176078241)

[8. Comments in Response to the Federal Register Notice and Efforts to Consult Outside the Agency](#_Toc176078242)

[9. Explanation of Any Payment or Gift to Respondents](#_Toc176078243)

[10. Assurance of Confidentiality Provided to Respondents](#_Toc176078244)

[11. Justification for Sensitive Questions](#_Toc176078245)

[12. Estimates of Annualized Burden Hours and Costs](#_Toc176078246)

[13. Estimates of Other Total Annual Cost Burden to Respondents and Record Keepers](#_Toc176078247)

[14. Annualized Cost to the Government](#_Toc176078248)

[15. Explanation for Program Changes or Adjustments](#_Toc176078249)

[16. Plans for Tabulation and Publication and Project Time Schedule](#_Toc176078250)

[17. Reason(s) Display of OMB Expiration Date is Inappropriate](#_Toc176078251)

[18. Exceptions to Certification for Paperwork Reduction Act Submissions](#_Toc176078252)

B**.** Collection of Information Involving statistical Methods

## 1. Respondent Universe and Sampling Methods

## 2. Procedures for the Collection of Information

## 3. Methods to Maximize Response Rates and Deal with Nonresponse

## 4. Test of Procedures or Methods to Be Undertaken

5. Individuals Consulted on Statistical Aspects and Individuals Collecting and/or Analyzing Data

References

**Exhibits**

Exhibit 8.1 Individuals Consulted During theDevelopment of Routine HIV Testing Campaign

Exhibit 8.2 Individuals Consulted During the Development of the PIC Campaign

Exhibit 12.1Estimated Annualized Burden Hours

Exhibit 12.2Estimated Annualized Burden Costs

Exhibit 14.1Estimated Cost to the Government

Exhibit 16.1Project Time Schedule

**LIST OF ATTACHMENTS**

1.Authorizing Legislation and Other Relevant Laws

2(a).Data Collection Instruments – Routine HIV Testing in Emergency Departments

2(b). Data Collection Instruments – Prevention is Care (PIC)

2(c). Data Collection Instruments – HIV Partner Services (Concept Testing)

2(d). Data Collection Instruments – HIV Partner Services (Materials Testing)

3(a).Federal Register Notices to the Public (30-day)

3(b).Federal *Register* Notices to the Public (60-day)

4.Institutional Review Board (IRB) Approval

5(a).Consent Forms – Routine HIV Testing in Emergency Departments

5(b).Consent Forms – Prevention is Care (PIC)

5(c).Consent Forms – HIV Partner Services

6(a).Study Screening Instruments – Routine HIV Testing in Emergency Departments

6(b).Study Screening Instruments – Prevention is Care (PIC)

6(c).Study Screening Instruments – HIV Partner Services

7(a).Paper and Pencil Survey – Routine HIV Testing in Emergency Departments

7(b).Paper and Pencil Survey – Prevention is Care (PIC)

7(c).Paper and Pencil Survey – HIV Partner Services

8. Privacy Agreement

**Formative Research to Develop Social Marketing Campaigns- Routine HIV Testing for Emergency Medicine Physicians, Prevention Is Care, and Partner Services**

# A. Justification

## 1. Circumstances Making the Collection of Information Necessary

The Centers for Disease Control and Prevention (CDC), Division of HIV/AIDS Prevention, requests a time extension for OMB 0920-0775 to continue a formative research study to support CDC’s efforts in further developing three social marketing campaigns targeting infectious disease specialists, primary care physicians, and emergency department physicians. The campaigns of focus remain the same: Routine HIV Testing, Prevention is Care (*PIC)* and Partner Services. To date, we have conducted a total of 162 interviews and have 82 remaining interviews to conduct. All exploratory research has been completed. The remaining interviews will be to finish creating materials for the three campaigns. The remaining interviews from 0920-0775 were not conducted due to budget reductions and eliminations. Therefore all materials were not developed. The materials to be tested will supplement the existing materials developed from the 162 interviews and will contain updated surveillance data, continue to promote CDC’s 2006 *Revised Recommendations for HIV Testing of Adults, Adolescents, and Pregnant Women in Health-Care Settings* among physicians in private practice and emergency departments and promote the new recommendations, if released in time. These materials will be used by the target audience to assist them with offering and conducting HIV prevention and testing. The remaining interviews are necessary to finish creating all of the materials and ensure the new materials are appropriate for the target audience.

Historically, prevention efforts have targeted people at risk for HIV infection with the goal of keeping those who are HIV negative from becoming infected. However, the epidemic has changed with the introduction of highly active anti-retroviral therapy. Despite advances in treatment and numerous prevention efforts, HIV continues to spread with an estimated 56,000 new HIV infections annually (Hall et al., 2008). An estimated 1.1 million Americans are living with HIV, and 1 out of 5 people with HIV do not know they have it (CDC, 2008). CDC’s goal, since 2001, has been to reduce the number of new HIV infections in the United States from an estimated 56,000 to 20,000 per year, focusing particularly on eliminating racial and ethnic disparities in new HIV infections.

Healthy People 2010 and 2020 objectives focus on preventing HIV infection and its related illness and death. In particular, Healthy People 2010 aimed to reduce the number of new cases of HIV/AIDS diagnosed among adult and adolescents and to increase the proportion of HIV-infected persons who know they are infected. Healthy People 2020 includes these objectives, as well as a new objective aiming to increase the proportion of adults and adolescents who have been tested for HIV in the past 12 months.

In 2010, the Office of National AIDS Policy out of the White House developed the *National HIV/AIDS Strategy (NHAS)* with three primary goals: 1) reducing the number of people who become infected with HIV; 2) increasing access to care and improving health outcomes for people living with HIV; and, 3) reducing HIV-related health disparities. In support of Healthy People 2010 and 2020 and the NHAS, CDC will finish developing all materials for the three campaigns targeting health care providers:

* **Routine HIV Testing:** The goal of this campaign is to increase HIV testing rates among those seeking emergency care services and those who may use emergency services to deliver their primary medical care needs. Those with a lower socioeconomic status (SES) are less likely to receive preventive care from primary care physicians (PCPs) or other health care providers outside emergency department settings, thus missing the opportunity for routine HIV screening. Research has found that persons with a lower SES often attend emergency departments for primary health care services (Alpert et al. 1996). Therefore, an emergency medicine physician has a unique opportunity to provide HIV screening services that a patient would otherwise not receive, or to counsel a patient to seek HIV testing.
* ***Prevention Is Care (PIC):*** *PIC* seeks to encourage Infectious Disease Specialists (IDS) and Primary Care Providers (PCPs) to screen their patients living with HIV for potential HIV transmission behaviors and deliver brief messages on the importance of protecting themselves and others by reducing their risky behaviors. Therefore, the goal of this campaign is to establish *PIC* as the standard of care for persons living with HIV.
* **Partner Services:** The goal of this campaign is to incorporate Partner Services into the care for persons diagnosed with HIV. Partner Services are a set of activities led by State Health Departments, and supported by healthcare providers, to notify the sex and drug-injection partners of HIV-positive persons that they have been exposed to HIV; offer them counseling, testing and referral services; and ensure that all HIV-positive persons are linked to appropriate medical care.

The following section of the U.S. Federal Code (see **Attachment 1**) is relevant to this data collection: 42 USC 241, Section 301 of the Public Health Service Act authorizes conduct of “research, investigations, experiments, demonstrations, and studies relating to the causes, diagnosis, treatment, control, and prevention of physical and mental diseases and impairments of man.”

## 2. Purpose and Use of the Information Collection

The purpose of this study is to continue one time semi structured in person in-depth interviews to finish developing all of the materials for the three social marketing campaigns (Routine HIV Testing, *PIC*, and Partner Services). RTI International, the evaluation contractor, will conduct the interviews and will interview each physician only once in order to finish developing all new campaign materials. We will continue to gain an understanding and identify physicians’:

* + Current practices (e.g., HIV testing, behavioral screening, partner notification and referral)
  + Use of HIV prevention and education materials with patients
  + Perceived and actual barriers to implementing new guidelines/recommendations
  + Initial reactions to campaign materials (e.g., visual appeal, format, design, content, usefulness, credibility)
  + Preferred channels for obtaining new information on guidelines or practices
  + Interest in provider resources and patient educational materials

The three social marketing campaigns will continue to increase the adoption of CDC’s 2006 *Revised Recommendations for HIV Testing of Adults, Adolescents, and Pregnant Women in Health-Care Settings* among physicians in private practice and emergency departments and the new recommendations, if released in time. All data collection instruments will remain the same, see **Attachment 2** for the data collection instruments. We will disseminate the final study results to the public once all formative research has been completed. The reports will be prepared for and/or by CDC or RTI and will be submitted to peer-reviewed journals where appropriate. All releases of information will be reviewed and approved by CDC.

## 3. Use of Improved Information Technology and Burden Reduction

The data collection requires that we continue to employ qualitative research methods through the use of one time in person in-depth interviews. The responses from the participants are as important as the interviewers’ observation of the participant and the overall interview. Where possible and upon consent from the participant, we will audio tape the interviews to capture all information and assist with preparation of reports.

## 4. Efforts to Identify Duplication and Use of Similar Information

In order to identify duplication and use of similar information, we conducted a review of the literature to update the existing literature review results. We continued to examine several large periodical journal databases and “gray” literature by exploring the Internet. Searches were performed on several Internet search engines, including Google, Yahoo, AltaVista, Medline, and Science Direct. We were unable to find duplication or the use of similar information. Therefore, we have confirmed the need to continue developing materials for the present study.

## 5. Impact on Small Businesses or Other Small Entities

## This study does not have impact on small businesses or other small entities. We will schedule all interviews at the convenience of the physician and we will not impact the physicians practice.

## 6. Consequences of Collecting the Information Less Frequently

This is an ad hoc data collection (i.e., a one-time study to develop three social marketing campaigns and does not require periodic collection of data). There are no legal obstacles to reduce burden. The present study will continue to provide data needed to develop additional materials for the Routine Testing, *PIC,* and Partner Services campaign materials. If we did not conduct this formative research, we would not be able to pre-test the additional campaign materials with the target audiences before they are widely distributed. Our formative research process includes gaining an understanding of a target audience’s perceived needs, benefits sought, and barriers of concern. Subsequently, materials are developed that are responsive to the target audience’s perspectives, needs, and concerns. We then test the materials with members of the target audience before they are widely disseminated (Slater, 1995). This project is critically important because it involves testing the additional materials that are being developed as part of the three social marketing campaigns described above.

## 7. Special Circumstances Relating to the Guidelines of 5 CFR 1320.5

There are no other special circumstances that require the data collection to be conducted in a manner inconsistent with 5 CRF 1320.5 (d)(2). This data collection request fully complies with the regulation.

## 8. Comments in Response to the Federal Register Notice and Efforts to Consult Outside the Agency

**A.** A 60-Day *Federal Register* notice for Formative Research to Develop the Routine HIV Testing for Emergency Medicine Physicians, *Prevention Is Care* (*PIC*), and Partner Services Social Marketing Campaigns—Extension— (0920–0775, exp. 4/30/2011) was published on December 3, 2010 (Volume 75, Number 232, pages 74574) and solicited comments. No comments were received. A copy of the 30 day and 60-day *Federal Register* notices can be found as **Attachments 3a and 3b** respectively.

**B.** The CDC study team collaborated with RTI International staff (evaluation contractor) on the study design, screening instruments, and interview guides. RTI staff is trained and experienced in formative research. CDC recognizes the importance of gaining valuable insights directly from members of the target audience and from organizations and individuals who work with them in the community. Consultation with individuals and related activities occurred for each campaign at various times in 2005 and 2006. Additional consultations occurred in 2010. All individuals consulted are listed below. No major problems were identified that could not be resolved.

At various points in 2005, 2006, 2009 and 2010 we consulted with the following individuals for development of the campaigns’ concepts, messages, and materials. Some materials have already been developed based on the 2005 and 2006 consultations and the formative research conducted in those years. In 2009 and 2010 we consulted with additional individuals for continued program direction and development of the remaining materials to be tested under this extension. See Exhibits 8.1 and 8.2 for individuals consulted by campaign in 2005, 2006, 2009 and 2010. We will continue to consult the individuals listed below as needed.

Exhibit 8.1. Individuals Consulted During the Development of Routine HIV Testing and Campaign

|  |  |
| --- | --- |
| **2005-2006 Individuals Consulted** | |
| Bernard M Branson, M.D.  Associate Director for Laboratory Diagnostics  Divisions of HIV/AIDS Prevention  National Center for HIV, STD and TB Prevention  Centers for Disease Control and Prevention  1600 Clifton Road  Atlanta, GA 30333  (404) 639-6166  BBranson@cdc.gov | Margaret Lampe, RN, MPH  Acting Team Lead, EPI Branch  Divisions of HIV/AIDS Prevention  National Center for HIV, STD and TB Prevention  Centers for Disease Control and Prevention  1600 Clifton Road  Atlanta, GA 30333  (404) 639-5189  MLampe@cdc.gov |
| **2009-2010 Individuals Consulted** | |
| Amir Qaseem, MD, PhD  Senior Medical Associate in the Clinical Program and Quality of Care Department of Medical Education and Publishing Division  American College of Physicians  190 North Independence Mall West  Philadelphia, PA 19106-1572  215-503-8575  Aqaseem@mail.acponline.org | Celia J. Maxwell, MD, FACP  Assistant Vice President for Health Sciences  Director of Women’s Health Institute  Howard University  1315 Leegate Road NW  Washington, DC 20012  202-865-7513  cmaxwell@howard.edu |
| Donna E. Sweet, MD, MACP  Professor of Medicine  The University of Kansas School of Medicine – Wichita  1010 N. Kansas  Wichita, Kansas 67214  316-268-5984  dsweet@kumc.edu | Jeffrey T. Kirchner, DO, AAHIVS  Medical Director of Comprehensive Care Center for HIV, Lancaster General Hospital  LGH Family & Community Medicine  555 North Duke Street,  PO Box 3555  Lancaster, PA 17604  717-544-4940  JTKirchn@LancasterGeneral.org |
| Jim Sosman, MD  Associate Director, HIV Care Program Associate Professor of Medicine, University of Wisconsin School of Medicine and Public Health  2828 Marshall Court, Suite 100  Madison, WI 53705  608-263-5259  Jms@medicine.wisc.edu | Joel Gallant, MD, MPH  Associate Director,  Johns Hopkins AIDS Service  1830 E. Monument Street  Room 443  Baltimore, MD 21205  410-955-7473  jgallant@jhmi.edu |
| Joseph McGowan, MD, FACP  Medical Director, NYS Designated AIDS Center  North Shore University Hospital 16 Country Club Lane  Briarcliff Manor, NY 10510  516-562-4280  JMcGowan@NSHS.edu | Lynn E. Sullivan, MD Assistant Professor of Medicine, Department of Internal Medicine, Yale University  367 Cedar Street  PO Box 208093  New Haven, CT 06520-8093  203-688-9105  lynn.sullivan@yale.edu |
| Margaret Hoffman-Terry, MD, AAHIVS  Chief of HIV Medicine  Lehigh Valley Hospital  413 N. Jasper St.  Allentown, PA 18109  610-969-2400  mhtc70@aol.com | Ron Goldschmidt, MD  Director, National HIV/AIDS Clinicians' Consultation Center (NCCC)Professor of Clinical Family and Community Medicine, Vice-Chair, UCSF Department of Family and Community Medicine  San Francisco General Hospital  1001 Potrero Avenue,  Building 80-83  San Francisco, CA 94110  415-206-5792  rgoldschmidt@nccc.ucsf.edu |
| Ronald Lubelchek, MD  Attending Physician  Division of Infectious Diseases  John H. Stroger Hospital of Cook County  1372 N. Dean Street, Apt. 1  Chicago, IL 60622  312-864-4590  rlubel@gmail.com | Wilbert Jordan, MD, MPH  Medical Director, Oasis Clinic  1807 E. 120th St.  Los Angeles, CA 90059  310-668-4213  tojo44@aol.com |
| Richard Rothman, MD, PhD  Johns Hopkins Department of Emergency Medicine5801 Smith Avenue, Suite 3220Davis Building  Baltimore, MD, 21209  410-735-6428  rrothman@jhmi.edu | Michael S. Lyons, MD,MPH Assistant Professor Department of Emergency Medicine University of Cincinnati College of Medicine  513-558-8629  lyonsme@ucmail.uc.edu |

**Exhibit 8.2. Individuals Consulted During the Development of the PIC Campaign**

|  |  |
| --- | --- |
| 2005-2006 Individuals Consulted | |
| Bernard M Branson, M.D.  Associate Director for Laboratory Diagnostics  Divisions of HIV/AIDS Prevention  National Center for HIV, STD and TB Prevention  Centers for Disease Control and Prevention  1600 Clifton Road  Atlanta, GA 30333  (404) 639-6166  BBranson@cdc.gov | Mark Thrun, M.D.—Medical Director, Denver STD/HIV Prevention Training Center  605 Bannock Street, MC 2600  Denver, CO 80204  (303) 436-7071  Mark.Thrun@dhha.org |
| Judith Absalon, M.D., MPH—Assistant Professor of Epidemiology, Mailman School of Public Health, Columbia University  722 West 168th St, Room 513  New York, NY 10032  (212) 342-0533  ja234@columbia.edu | Howard Grossman, M.D.—Executive Director, American Academy of HIV Medicine  1705 DeSales Street, Suite 700  Washington, DC 20036  (877) 422-4486  howard@aahivm.org |
| Wayne Bockmon, M.D.—Staff Physician, Montrose Clinic  4706 Westslope Circle  Austin, TX 78731  (512) 420-2314  kwb@austin.rr.com | Peter Meacher, M.D.—Medical Director, South Bronx Health Center for Children and Families, Montefiore Medical Center  871 Prospect Avenue  Bronx, NY 10459  (718) 991.0605 x 236  pmeacher@montefiore.org |
| Alwyn Cohall, M.D.—Associate Professor, Harlem Health Promotion Center, Mailman School of Public Health, Columbia University  215 West 125th Street New York, NY 10027 (646) 284-9725 atc1@columbia.edu | Peter Shalit, M.D., Ph.D.—Physician, Swedish Medical Center  1120 Cherry Street, #320  Seattle, WA 98104  (206) 624-0688  psmd@mac.com |
| Donald T. Evans, M.D.—Physician, Founder, AIDS Project Greater Danbury  115 Mount Pleasant Rd.  Newton, CT  (203) 426-5626  apgd99@aol.com |  |
| 2009-2010 Individuals Consulted | |
| John Bartlett  Chief, Professor of Medicine  Division of Infectious Diseases Johns Hopkins University School of Medicine  1830 E. Monument St.  RM 439  Baltimore, MD 21205  410.955.7634  jb@jhmi.edu | Constance Benson  Professor of Medicine  UCSD Antiviral Research Center Department of Medicine  Mail Code 8208150 West Washington Street, Suite 100  San Diego, CA 92103  (619) 543-8080  cbenson@ucsd.edu |
| Wayne Bockmon  Practicing Physician  Montrose Clinic  4706 Westslope Circle  Austin, TX 78731  512.420.2314 (Home)512.350.6911 (Cell)  kwb123@gmail.com | John Brooks  Leader, Clinical Epidemiology Team  Division of HIV/AIDS Prevention, NCHSTP  Centers for Disease Control and Prevention1600 Clifton Rd., MS E-45  Atlanta, GA 30333  404.639.3894  zud4@cdc.gov |
| Kevin Charmichael  Chief of Service  El Rio Special Immunology Associates1701 W. St. Mary's Road, Suite 160  Tuscon, AZ 85745  520.628.8287  kevinc@elrio.org  jkcsia@elrio.org | Alwyn Cohall  Associate Professor of Clinical Public Health and Clinical Pediatrics  Mailman School of Public Health of Columbia University  215 West 125th St., Ground Floor  New York, NY 10027  646.284.9725  atc1@columbia.edu |
| Eric Daar  Director of the Division of HIV Medicine  Harbor-UCLA Medical Center, Box 400  1000 W. Carson Street  Torrence, CA 90509  310.222.2401  edaar@labiomed.org | David Hardy  Associate Professor of Medicine  Cedars-Sinai Medical Center Infectious Diseases  8700 Beverly Bl, #B-220  Los Angeles, CA 90048  310.423.3896  david.hardy@cshs.org |
| Peter Meacher  Practicing Physician  South Bronx Health Center for Children and Families  Montefiore Medical Center  871 Prospect Ave.  Bronx, NY 10459  718.991.0605 x 236  pmeacher@montefiore.org | Evelyn Quinlivan  Assistant Professor of Medicine  Director, Infectious Diseases Clinic  School of Medicine  The University of North Carolina at Chapel Hill  Bioinformatics Building  130 Mason Farm Road  Campus Box 7030  Chapel Hill, NC 27599  919.966.2536  ebq@med.unc.edu |
| Peter Shalit  Practicing Physician Swedish Medical Center  1120 Cherry Street, #320  Seattle, WA 98104  206.624.0688  psmd@mac.com | Mark Thrun  Medical Director, HIV Prevention  Denver STD/HIV Prevention Training Center  605 Bannock Street, MC 2600  Denver, CO 80204  303.436.7071  303.602.3645 (NEW)  Mark.Thrun@dhha.org |
| Kimberly Smith  Rush University Medical Center  600 S. Paulina Street, Suite 143  Chicago, Illinois,60612  312-942-5865  Kimberly\_Y\_Smith@rush.edu | Kathleen E. Squires  1339 Chestnut St.  Philadelphia, PA 19107  215-627-0321  Kathleen.Squires@jefferson.edu |

## 

In addition, we will continue to consult with representatives from state health departments on an ongoing basis throughout the campaign development process to ensure that their perspectives are incorporated into the development of the campaign materials.

## 9. Explanation of Any Payment or Gift to Respondents

We will give all participants a token of our appreciation.

Emergency medicine physician interview $200

PCP interview $150

IDS interview $250

The tokens of appreciation were determined based upon the burden to the participants, taking into account that the participants are physicians, the length of the interview, the fact that participants may have to travel a considerable distance to and from the focus group facility, parking costs, and our previous experience conducting interviews with PCPs and IDS. This is intended to recognize the time burden placed on the participants, encourage their cooperation, and to convey appreciation for contributing to this important study. Numerous empirical studies have shown that honoraria can significantly increase response rates (e.g., Abreu & Winters, 1999; Shettle & Mooney, 1999; Greenbaum, 2000). Physicians are a difficult population to reach because they are highly paid and their time is at a premium. They are frequently bombarded by numerous entities all requesting their time for interviews, surveys and pharmaceutical sales presentations. As a result, they often decline to participate.

Our experience has shown that a smaller token of appreciation does not appear sufficiently attractive to physicians especially given that a higher number of physicians are now paid on a fee-for-service basis, and may be reluctant to leave their office for an interview. For example, if a physician sees a minimum of four patients an hour, each with an average billing rate of $50, this equates to a physician hourly rate of $200 without leaving the office. Suggested standard rates range from $200 to $250 for physicians (Slaughter, et. al, 1999). This amount is consistent with quotes RTI received in 2006 from focus group facilities for recruiting PCPs and IDS. Higher amounts may be necessary to recruit physicians who see a higher number of patients per hour or who have additional years of specialized training, such as IDS. We also believe that the token of appreciation will result in higher data validity as physicians become more engaged in the interview process. Participants will receive their token of appreciation immediately after completing their participation in the interview.

## 10. Assurance of Confidentiality Provided to Respondents

This data collection has received NCHHSTP Project Determination approval as a part of a larger project determination focusing on medical providers. See **Attachment 4**.

In review of this application, it has been determined that the Privacy Act is not applicable.

The contractor RTI will utilize names and addresses to send reminder letters/e-mails and make reminder phone calls, but the information will not be recorded on the actual surveys. All questionable data and the personal identifiers needed to locate potential participants will be stored in separate locked file cabinets in locked offices in a secured facility. All electronic files will be password controlled and only accessible to fully authorized personnel and maintained and protect to the extent allowed by law.

RTI will select and reserve focus group facilities in each city for each of the three campaigns, overseeing the local focus group facilities’ recruitment of participants. Recruitment staff will receive extensive instruction on the importance of maintaining data in a secure manner at all times. Furthermore all employees who work on this study will be required to sign a Privacy Agreement (**Attachment 8**). RTI and the focus group facilities will use screening instruments to identify eligible participants for the study. As participants are recruited, recruitment grids will be prepared to keep track of the recruitment, listing the participants’ first name and some demographic obtained from the screener. The recruitment grid will be stored in a locked file cabinet or on a password protected project share drive at RTI, each focus group facility will destroy their copy of the recruitment grid after data collection has been completed. Copies of the recruitment grid will be provided to RTI and CDC for description of the study sample, which will be kept in locked file cabinets or on a password protected project share drive at RTI and CDC for the duration of the study.

No identifying information will be kept at the focus group facilities after the interviews are completed and the focus group facilities will not send any identifying information to RTI or CDC.

Once the potential participant comes to the study site and checks in, he/she will be given a consent form. The individual will be given time to read the consent form on his/her own and a trained RTI staff member will be available to answer any questions. If the participant agrees to be in the study, he/she will sign the consent form and be given a copy to keep for his/her records. Participants will be reminded that they can refuse to answer any question and they can stop being in the study at any time, without penalty. RTI staff will FedEx or personally take these forms back to RTI after the interviews are completed in each city. The consent forms will be stored in a locked file cabinet at RTI for the duration of the project. Once the project ends, the forms will be transferred to a locked RTI storage facility for three years. After three years, RTI staff will destroy the forms.

## 11. Justification for Sensitive Questions

Sensitive information will not be collected as part of this study.

## 12. Estimates of Annualized Burden Hours and Costs

The total annualized response burden is estimated at 115 hours. There is no change to the estimated total annualized response burden hours or cost as a result of the extension request. **Exhibits 12.1 and 12.2** provide details about how this estimate was calculated. Timings were conducted during our instrument development process to determine the overall burden per respondent. Administration of the screening instrument is estimated to take 10 minutes. Participation in an interview is estimated to take 1 hour. Each year we will complete 123 screening questionnaires (20 hours) and 82 physicians will participate in an interview (82 hours), and take a 10 minute paper and pencil survey (13 hours) totaling 115 hours. Each participant will also complete a 5 minute consent form (7 hours).

**Exhibit 12.1. Estimated Annualized Burden Hours**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Type of Respondent** | **Form Name** | **No. of Respondents** | **Responses Per Respondent** | **Average Burden Per Response (in hours)** | **Total Burden Hours** |
| Emergency Medicine Physicians | Routine HIV Testing Screener | 12 | 1 | 10/60 | 2 |
| Routine HIV Testing Interview | 8 | 1 | 1 | 8 |
| Routine HIV Testing Paper & Pencil Survey | 8 | 1 | 10/60 | 1 |
| Prevention Is Care | *PIC* Screener | 72 | 1 | 10/60 | 12 |
| *PIC* Interview | 48 | 1 | 1 | 48 |
| *PIC* Paper & Pencil Survey | 48 | 1 | 10/60 | 8 |
| Partner Services | Partner Services Screener | 39 | 1 | 10/60 | 6 |
| Interview  (*Concept Testing*) | 13 | 1 | 1 | 13 |
| Interview  (*Materials Testing*) | 13 | 1 | 1 | 13 |
| Partner Services Paper & Pencil Survey | 26 | 1 | 10/60 | 4 |
|  | Total |  |  |  | 115 |

In calculating the burden, we used the amount of $66.79 per hour as an estimate of the average physician’s hourly wage rate. We will continue to use the mean hourly wage for physicians and surgeons released from the United States Department of Labor, Bureau of Labor Statistics (May, 2005). Available online at: http://www.bls.gov/oes/current/oes291069.htm. Actual hourly wage rates will vary by physician credentials (e.g., wage rates for IDS may be higher than the wage rates for PCPs). The estimated annual cost to participants for the hour burden for collections of information will be $7,757.00.

Exhibit 12.2 Estimated Annualized Burden Costs

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Respondents** | **Activity** | **No. of Respondents** | **No. of Response per Respondent** | **Average Burden per Response**  **(in Hours)** | **Total Burden Hours** | **Hourly Wage Rate\*** | **Total Respondent Costs\*\*** |
| Routine HIV Testing in Emergency Departments | Screener | 12 | 1 | 10/60 | 2 | $66.79 | $134 |
| Interview  (Material Testing) | 8 | 1 | 1 | 8 | $66.79 | $534 |
| Paper and Pencil Survey | 8 | 1 | 10/60 | 1 | $66.79 | $89 |
| Prevention Is Care (PIC) | Screener | 72 | 1 | 10/60 | 12 | $66.79 | $801 |
| Interview  (MaterialTesting) | 48 | 1 | 1 | 48 | $66.79 | $3,206 |
| Paper and Pencil Survey | 48 | 1 | 10/60 | 8 | $66.79 | $534 |
| HIV Partner Services | Screener | 39 | 1 | 10/60 | 6 | $66.79 | $434 |
| Interview  (*Concept Testing*) | 13 | 1 | 1 | 13 | $66.79 | $868 |
| Interview  (*Material Testing*) | 13 | 1 | 1 | 13 | $66.79 | $868 |
| Paper and Pencil Survey | 26 | 1 | 10/60 | 4 | $66.79 | $289 |
| **Total** |  |  |  |  | **115** |  | **$7,757** |

## 13. Estimates of Other Total Annual Cost Burden to Respondents and Record Keepers

Respondents participate on a purely voluntary basis and, therefore, are subject to no direct costs other than their time to participate; there are no start-up or maintenance costs. We do not require any additional record keeping.

## 14. Annualized Cost to the Government

The total annualized cost for the remainder of this study is estimated to be $293,652. This includes the CDC FTEs and a contractor (**see Exhibit 14.1**). Details of the annualized costs are contractor’s costs are based on estimates provided by the contractor who will carry out the data collection activities. This is the cost estimated by the contractor, RTI, and includes the estimated cost of coordination with the CDC, data collection, analysis, and reporting.

**Exhibit 14.1. Estimated Cost to the Government**

|  |  |  |
| --- | --- | --- |
| **Expense Type** | **Expense Explanation** | **Annual Costs (dollars)** |
| ***Direct Cost to the Federal Government*** | | |
| * CDC oversight of contractor and project | CDC Project Officer | $60,521 |
|  | CDC Co-Principal Investigator | $59,295 |
| *Subtotal, Direct Costs to the Government* | | *$119,816* |
| ***Contractor and Other Expenses*** | | |
| * Recruitment and Data Collection (Contractor) | Labor hours and Other Direct Costs | $130,380 |
| * Analysis and Reporting (Contractor) | Labor hours and ODCs | $43,456 |
| *Subtotal, Contracted Services* | | *$173,836* |
| **TOTAL COST TO THE COVERNMENT** | | **$293,652** |

## 15. Explanation for Program Changes or Adjustments

This is a request for a three year time extension. There is no change in burden requested or associated costs. The remaining interviews will be conducted to finish creating materials for the three campaigns. The remaining interviews from 0920-0775 were not conducted due to budget reductions and eliminations. Therefore all materials were not developed.

## 16. Plans for Tabulation and Publication and Project Time Schedule

Data from the interviews will be entered into an electronic data matrix by the RTI note taker during the data collection and stored on a password protected computer. Analysis of the interview data will start immediately after completion of data collection in each city and will be conducted under the supervision of a senior staff member with extensive experience in qualitative research. RTI will conduct thematic or ground theory analysis of the data to understand participants’ reactions to the campaign messages in as rigorous and detailed manner as possible. RTI and CDC will review the preliminary data within one week after data collection is completed in each city via a debriefing conference call. RTI analysts will further analyze the data in the matrices and summarize results in three separate topline reports by phase and one final report. Data from the paper and pencil questionnaires will be keyed into Microsoft Excel and be reported in descriptive data tables with accompanying narrative in the topline and summary reports. The key events and reports to be prepared are listed in **Exhibit 16.1.**

Exhibit 16.1. Project Time Schedule

|  |  |
| --- | --- |
| **Activity** | **Time Schedule** |
| Identify and reserve focus group facilities | 1 month after OMB approval |
| Begin recruitment | 1 month after OMB approval |
| Phase 1: Conduct interviews | 2 months after OMB approval |
| Phase 1: Topline report due | 4 months after OMB approval |
| Phase 2: Conduct interviews | 17 months after OMB approval |
| Phase 2: Topline report due | 19 months after OMB approval |
| Phase 3: Conduct interviews | 32 months after OMB approval |
| Phase 3: Topline report due | 34 months after OMB approval |
| Summary report due | 35 months after OMB approval |

## 17. Reason(s) Display of OMB Expiration Date is Inappropriate

We do not seek approval to eliminate the expiration date.

## 18. Exceptions to Certification for Paperwork Reduction Act Submissions

There are no exceptions to the certification statement.